Diabetes & Endocrinology · page 3
Once-weekly insulin plus GLP-1 beats daily glargine at insulin start
COMBINE 4 gives better HbA1c, weight and hypoglycaemia in one weekly injection. The Diabetes Prevention Program at 25 years says lifestyle, not metformin, holds down chronic disease. And Cochrane finds the case for bariatric surgery in diabetes rests on thinner evidence than most counselling assumes.
A once-weekly insulin-GLP-1 combination beats daily glargine, and the lipid goalposts move
COMBINE 4 shows once-weekly icodec plus semaglutide outperforming daily glargine on HbA1c, weight and hypoglycaemia. Meanwhile the 2026 dyslipidaemia guideline pulls millions of lower-risk adults into statin therapy, and two safety reviews sharpen what to watch on incretins and SGLT2 inhibitors.
Twenty-five years on, lifestyle kept the illnesses away and metformin did not
The Diabetes Prevention Program's Medicare follow-up finds a lasting cut in multimorbidity from lifestyle alone. A once-weekly insulin-plus-semaglutide combination beats daily glargine on HbA1c, weight and hypoglycaemia. And the 2026 lipid guideline makes 21.5 million more adults statin-eligible.
An oral GLP-1 finds its place on top of basal insulin
ACHIEVE-5 puts orforglipron alongside titrated glargine and cuts HbA1c by roughly a further percentage point. Finerenone's albuminuria benefit holds in type 1 diabetes regardless of glycaemic control.